Market Research Report
Global Autoimmune Drugs Market 2018-2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||354855|
|Published||Content info||124 Pages
Delivery time: 1-2 business days
|Global Autoimmune Drugs Market 2018-2022|
|Published: December 14, 2018||Content info: 124 Pages||
High cost of autoimmune drugs to drive market growth. Governments and regulatory bodies have undertaken several initiatives to reduce the costs of therapies for autoimmune disorders mainly rheumatoid arthritis. Despite these efforts, autoimmune drugs continue to remain expensive. Biologics and biosimilars are expensive when compared with conventional therapies such as NSAIDs. Technavio' s analysts have predicted that the autoimmune drugs market will register a CAGR of more than 8% by 2022.
By providing a targeted action, biologics tend to be more effective and have lesser side effects compared with small molecule agents. Hence, the introduction of biologic therapy to manage autoimmune disorders is driving the market at a very rapid pace.
The insurers are reluctant to provide reimbursement for the drugs for treatment of autoimmune diseases due to the lack of knowledge; therefore, they generally do not provide any provisions for the reimbursement of drugs for rheumatoid arthritis and other autoimmune diseases.
For the detailed list of factors that will drive and challenge the growth of the autoimmune drugs market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company the competitive environment is quite intense. Factors such as the targeted therapeutic mechanism of biologics and the high cost of autoimmune drugs, will provide considerable growth opportunities to autoimmune drugs manufactures. AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB are some of the major companies covered in this report.